Dsm-firmenich Ag · EURONEXT:DSFIR
Dsm-firmenich — Shareholder Meeting (June 2023)
20 slides from Dsm-firmenich's shareholder meeting presentation, Jun 23, 2023
Slide 1: We bring progress to life
We bring progress to life
Slide 2: A leading creation and innovation partner in health, nutrition and beauty
A leading creation and innovation partner in health, nutrition and beauty ~30,000 150+ years €12+ bn passionate, talented, of combined scientific combined revenue and diverse people in discovery and our global team innovation heritage Locally relevant co-creation and innovation with customers Pionee
Slide 3: Four high-performing and complementary businesses uniquely positioned to address consumer trends
Four high-performing and complementary businesses uniquely positioned to address consumer trends Perfumery Taste, Texture Health, Nutrition Animal Nutrition & Beauty & Health & Care & Health 29% 24% 18% 29% % of 2022FY pro-forma revenues 3
Slide 4: We have great products and solutions to bring progress to life: Fame
We have great products and solutions to bring progress to life Fame by Paco Rabanne 4
Slide 5: We have great products and solutions to bring progress to life: Actimel
We have great products and solutions to bring progress to life Actimel® containing Ingredients and Taste Solutions and made with Bovaer® 5
Slide 6: We have great products and solutions to bring progress to life: Culturelle
We have great products and solutions to bring progress to life Culturelle® number 1 selling probiotic brand in the world. 6
Slide 7: We have great products and solutions to bring progress to life: Veramaris
We have great products and solutions to bring progress to life Veramaris®, Algae-based omega-3 oil ensures health and optimum growth of salmon and reduces the amount of wild-caught fish 7
Slide 8: Proven science that improves lives
Proven science that improves lives Today’s challenges demand visionary solutions With over a century of world-class scientific leadership, we apply creativity and proven science to tackle complexity using the broadest portfolio of ingredients in our industry 15 2,000+ 16,000+ €700m+ R&D facilities o
Slide 9: Science Video
Science Video 9
Slide 10: A global vertically integrated supply chain
A global vertically integrated supply chain 88 Manufacturing sites North America EMEA 78 Creation Application 6 9 Creation 19 Application labs Premix 7 Application 34 Premix 21 Manufacturing sites 24 Manufacturing sites 31 40 Creation centers APAC Creation 13 Latin America 70 Creation 2 Application
Slide 11: Doing good, better than ever – stronger together
Doing good, better than ever – stronger together World-leading Global recognition partnerships P:\PresentationCenter\London P - arisMaterials\ Brunello - UN Sustainabili tyWheel\UN SustainabilityWheel.ai Please note that some of the achievements mentioned in this context were attributed to DSM and s
Slide 12: The world today: The Desirable, The Essential, The Sustainable
The world today… The Desirable The Essential Want Need The Sustainable Should and Must
Slide 13: We bring progress to life – Our purpose
Our purpose We bring progress to life
Slide 14: dsm-firmenich on one page
dsm-firmenich on one page We bring progress to life Essential Desirable Sustainable NEED WANT MUST Together, with our customers Shape the Be a force Own the future for good outcome 14
Slide 15: Operating model
Operating model ‘The Group has Business-led Business Partners Right Decision priority’ Unless Enable Excellence at the Right dsm-firmenich operates as one Business Units have a high degree of and Efficiency Level Business Partners provide Regional and local group that drives the autonomy to ensure k
Slide 16: Synergies - driving substantial value creation with low integration risk
Synergies - driving substantial value creation with low integration risk Revenue Synergy Breakdown Substantial Value Creation ~€500m Sales Revenue 60% Taste, Texture & Health synergies ~50 – 60% 25% Health, Nutrition & Care ~40 – 50% cost synergies 15% Perfumery & Beauty Total run-rate ~€350m synerg
Slide 17: Update on current trading
Update on current trading Trading update Q2 2023 Outlook for 2023 FY dsm-firmenich expects on a pro-forma basic: dsm-firmenich expects on a pro-forma basic: Adj. EBITDA Q2 2023: €400-420 Adj. EBITDA 2023: €1,800-1,900 (€521m in Q1 2023, €582m in Q2 2022) (€2,275m FY 2022) Within this, the company es
Slide 18: Strategic actions
Strategic actions dsm-firmenich will accelerate actions to increase the earnings quality by reducing its exposure to vitamins and resulting earnings volatility Prioritize Organization Asset Cash Program Adaptation New Vitamin Working Vitamin of ANH separate footprint capital Transformation strategy
Slide 19: Robust financial profile for superior shareholder value creation
Robust financial profile for superior shareholder value creation Mid-single-digit percentage of organic sales growth moving to Sales Mid-Term a 5-7% range, supported by revenue synergies and innovations Financial Objectives1 Adjusted EBITDA Margin moving to the 22-23% range, supported EBITDA by syne
Slide 20: We bring progress to life
We bring progress to life by combining the Essential, the Desirable and the Sustainable